• Cigna Q3 2026 Earnings Analysis
    Nov 6 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to listen to. I'm Alex...

    **JORDAN:** ...and I'm Jordan. Today we're digging into Cigna's third quarter 2026 results, and Alex, this is a company that's raising guidance while also telling investors "hey, 2027 is going to be a little weird."

    **ALEX:** Exactly, lots to unpack. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Good to have that out of the way. So let's get into the numbers.

    **ALEX:** Cigna posted adjusted revenue of $73.8 billion for the quarter, adjusted after-tax earnings of $2.1 billion, and adjusted EPS of $7.98. And here's the headline: they raised full-year 2026 EPS guidance to at least $30.60.

    **JORDAN:** That's a nice beat-and-raise story. And it's coming from two engines — Evernorth, their health services and pharmacy arm, and Cigna Healthcare, the traditional insurance side. Evernorth revenue grew 6% to $63.8 billion, with pretax earnings of $1.8 billion. Cigna Healthcare revenue was up 9% to $11.7 billion, pretax earnings of $1.2 billion.

    **ALEX:** And within Evernorth, the real star was Specialty and Care Services — that's Accredo, their specialty pharmacy, and CuraScript, their distribution business. Pretax earnings there grew 15% year-over-year to $1.1 billion.

    **JORDAN:** That's being driven by biosimilars and specialty generics hitting their stride. Generic Revlimid, a big oncology drug, is now at about 90% penetration. Biosimilar Humira and Stelara are seeing strong adoption too, especially with Cigna offering zero-dollar out-of-pocket options for patients.

    **ALEX:** It's a good reminder that the "boring" parts of healthcare — drug substitution, supply chain efficiency — can actually be huge profit drivers.

    **JORDAN:** Right, and on the Cigna Healthcare side, their medical care ratio — basically how much premium revenue goes out the door in claims — came in at 85%, right in line with expectations. Medical customers grew 2% year-to-date to 18.5 million, with particularly strong growth in their Select segment, which serves smaller employers.

    **ALEX:** Now let's talk strategy, because CEO Brian Evanko spent a lot of time on something called "Lead to 1." It's their big vision going forward.

    **JORDAN:** Lead to 1 is essentially about personalization at scale using data and AI. The stat that jumped out at me: 8% of patients account for 55% of total healthcare spending. So the whole strategy is built around identifying those complex, high-cost patients earlier and intervening before costs spiral.

    **ALEX:** They launched something called HealthSense in September — a tool that connects a patient's health needs, benefits, pharmacy coverage, and claims history so clinical teams get the full picture. It's starting with oncology.

    **JORDAN:** And they gave some compelling numbers around this — an integrated cancer patient journey can save $28,000 per person per year. That's not a typo, that's the scale of savings they're talking about for complex care coordination.

    **ALEX:** The other big strategic story is the "Signature" model — this is Cigna's attempt to reinvent pharmacy benefits. Instead of the traditional rebate-driven system, it's a fee-based, transparent model.

    **JORDAN:** Which matters because, let's be honest, PBMs have taken a lot of regulatory and public heat for opacity. Signature is designed to guarantee patients the lowest available out-of-pocket cost on prescriptions — they're calling it "Price Assure," and it's already saving about 30% on high-cost branded drugs for the rou

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Stryker Q3 2026 Earnings Analysis
    Oct 30 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Stryker's third quarter 2026 results. There's a lot to unpack here—an orthopaedics slowdown, a big robotics announcement, and a CEO transition all in one call.

    But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Right, and this one's actually a pretty meaty transcript, Alex. It's Kevin Lobo's last earnings call as CEO—57 quarters, which is a wild number—before he hands the reins to Spencer Stiles. So there's a bit of a "passing the torch" energy, but also some real business headwinds to address.

    **ALEX:** Let's start with the numbers. Stryker posted organic sales growth of 7.7% for the quarter. Adjusted EPS came in at $3.52, up about 10% year-over-year. On the surface, that sounds pretty solid.

    **JORDAN:** It does, but the devil's in the segment details. MedSurg and Neurotechnology grew 9.1%—that's the strong part of the story. Endoscopy was up double digits in the U.S., Medical grew 10%, Vascular grew 13%. But Orthopaedics—their bread-and-butter joint replacement business—only grew 5.9%, and within that, U.S. Knees were up just 1.3% and U.S. Hips actually declined slightly.

    **ALEX:** And that's really the headline story here, right? Management flagged a genuine market slowdown in U.S. hip and knee procedures.

    **JORDAN:** Exactly. Kevin Lobo was pretty candid about it. He pointed to patient affordability issues—higher deductibles, higher premiums—plus an uptick in insurance pre-authorization denials that's delaying patients from getting procedures done. He estimated the overall hip-and-knee market is now growing around 2.5%, which is a notable step down from the 5-6% range we've seen in recent years.

    **ALEX:** And it wasn't just market softness—Stryker also admitted they're not winning share at their historical pace.

    **JORDAN:** Right, and they were refreshingly honest about why. 2026 has been a messy year operationally. There was the cyber incident back in Q1, and then in July they completed their final SAP system implementation within Orthopaedics. Management said that actually delayed their visibility into real-time market conditions—they didn't fully grasp the slowdown until September, during an investor conference.

    **ALEX:** That's a pretty candid admission—basically saying "we were flying partially blind on our own numbers."

    **JORDAN:** It is. And it ties into why new products like Mako RPS and Triathlon Gold haven't scaled as fast as hoped—not a product problem, they said, but a commercial execution and distraction problem. The silver lining: they're bringing a power hip impaction tool to market next year, which fills a real gap in their hip portfolio and could help with competitive conversions.

    **ALEX:** Let's talk strategy, because there were two notable moves this quarter. First, they closed the acquisition of ZuriMED, which brings fiber-locker technology for rotator cuff repair—plugging nicely into their existing shoulder and sports medicine business.

    **JORDAN:** The bigger one, though, is the strategic investment in CMR Surgical. Stryker is becoming the exclusive U.S. sales agent for CMR's Versius soft-tissue robotic platform. This is interesting because Lobo was very clear this is intentionally structured to be low-risk—they're an investor and commercial partner for now, not an outright owner.

    **ALEX:** Why not just buy the whole thing?

    **JORDAN:** Lobo explained it well—he called it "derisking." Developing a soft-tissue robot from scratch is expensive and uncertain, and this lets Stryker test c

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Boston Scientific Q3 2026 Earnings Analysis
    Oct 28 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Boston Scientific's third quarter 2026 results. And folks, there's a lot going on here — a cyber incident, competitive pressure, and some pretty candid talk about 2027 being a tough year. But before we get into it...

    This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Alright, let's set the scene. Boston Scientific, ticker BSX, has been a Wall Street darling for years — consistent growth, strong execution. But this quarter was rough.

    **ALEX:** Rough is right. Organic revenue grew just 1.5%, way below their guided range of 3% to 5%. Adjusted EPS came in at 73 cents, down 3% year-over-year, versus a guide of 80 to 82 cents.

    **JORDAN:** And the big culprit here is this cybersecurity incident that forced an operational outage. For about two weeks, they literally couldn't manufacture or ship product in some cases.

    **ALEX:** Right, management says that knocked off roughly 300 basis points of revenue growth and about 7 cents of EPS in the quarter. The good news — operations were fully back online by September 8th. But here's the kicker: the pain doesn't stop there. They're expecting another 200 to 300 basis points of headwind in Q4 because customers over-ordered at the end of Q3 to restock inventory, and now that has to normalize.

    **JORDAN:** It's like a hangover from the outage. You binge-order to protect your supply chain, and then the following quarter you're just burning through that excess inventory instead of placing new orders.

    **ALEX:** Exactly. And that's part of why Q4 guidance is actually a revenue *decline* — negative 1% to negative 3% organically, with EPS of 77 to 79 cents. For the full year 2026, they're now looking at about 4% organic growth and EPS of $3.16 to $3.18.

    **JORDAN:** Now, cyber incident aside, there's a bigger structural story here, and I think this is really the headline of the call. Two of their biggest growth engines over the last few years — Watchman, the left atrial appendage closure device, and their electrophysiology business built around FARAPULSE — are now dragging down total company growth.

    **ALEX:** Yeah, let's talk about EP first because that one's a bit alarming. Sales declined 5% year-over-year, down 8% in the U.S. Management openly admitted they're losing share as new pulsed-field ablation competitors enter the market with different catheter designs. And here's the thing — they don't expect real relief until they launch FARAWAVE Ultra, which got pushed to early 2028. Originally that was supposed to be sooner.

    **JORDAN:** And it's not just Ultra — their next-gen wide-area catheter, FARAFLEX, is now a 2029 launch. CEO Mike Mahoney and CFO John Monson were pretty transparent that pipeline timing has been a problem. Executive Joe Fitzgerald explained some of the delays — Ultra's held up by design verification and validation work, while FARAFLEX has had FDA negotiation delays and some operational hurdles in scaling up the clinical trial.

    **ALEX:** And then there's Watchman — down 7% in the U.S., though international grew 4%. Management's take is that physicians are reassessing referral patterns based on recent clinical evidence, and that's slowing the whole left atrial appendage closure market down, not just Boston Scientific specifically.

    **JORDAN:** They're throwing resources at it though — over 200 medical education events last quarter alone, more dedicated sales reps, and they've got a next-gen Watchman FLX Pro platform in a clinical trial now, aiming for a 2029 launch.

    **ALEX:** So here's where it gets really interest

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
  • Thermo Fisher Scientific Q3 2026 Earnings Analysis
    Oct 21 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Thermo Fisher Scientific's third quarter 2026 results — and Jordan, this is a good one.

    **JORDAN:** Oh, it's a good one. Beat and raise, strong end markets, tariff refunds... there's a lot to unpack.

    **ALEX:** There really is. But before we get into it — quick reminder for everyone listening: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Important stuff, let's get into the numbers.

    **ALEX:** Okay, so headline numbers first. Revenue came in at $12.14 billion, up 9% year-over-year. Adjusted EPS grew 15% to $6.68 per share. And adjusted operating margin expanded 120 basis points to 24.5%.

    **JORDAN:** And here's the thing — this wasn't just "in line" or a small beat. CFO Jim Meyer said Q3 revenue came in more than $200 million ahead of their prior guidance, and EPS beat by $0.26. That's a real beat.

    **ALEX:** Right, and there's an interesting wrinkle in that EPS beat. $0.08 came from genuinely strong operational execution, $0.03 from foreign exchange, but $0.15 — more than half — came from tariff refunds that got recovered in the quarter.

    **JORDAN:** Yeah, that tariff refund piece is worth sitting with for a second. Management said they received approvals on the vast majority of their total potential refund claims this quarter. That added about $60 million to adjusted operating income — roughly 50 basis points of margin. But here's what I liked: they didn't just drop it straight to the bottom line. They reinvested a chunk of it into AI deployment, capacity scale-up in Pharma Services, and employee investments.

    **ALEX:** Which tells you management is thinking medium-term, not just trying to make this quarter look good.

    **JORDAN:** Exactly. It's a one-time windfall, and they treated it like one — put it to work rather than just banking it.

    **ALEX:** Let's talk end markets, because this is really the heart of the story. Pharma and biotech — their biggest and most important market — grew high single digits, led by Pharma Services and the research and safety channel. Academic and government was flat, which was expected. Industrial and applied grew high single digits, driven by electron microscopy and semiconductor demand. And diagnostics and healthcare grew low single digits.

    **JORDAN:** The pharma and biotech story is the one analysts kept circling back to in the Q&A. CEO Marc Casper talked about this almost like a staged recovery — first you saw clinical trial authorizations pick up, then lab-based research activity in biotech, and now they're expecting the high-end reagents business to be the next leg of that recovery over the next couple of quarters.

    **ALEX:** It's basically a domino effect working through the biotech funding recovery.

    **JORDAN:** And geographically, Asia Pacific — including China — grew low double digits. That's notable. China's been a wildcard for a lot of life sciences companies, and Thermo's seeing real strength there.

    **ALEX:** Now let's talk strategy, because there were some real moves this quarter. The Clario acquisition — that's the clinical research technology business — integration is going smoothly, and management's already talking about revenue synergies building.

    **JORDAN:** They also hit the one-year anniversary of the filtration and separation business acquisition, which they said strengthened their bioproduction capabilities. And on the flip side, they completed the divestiture of the microbiology business — which actually dragged reported revenue down about 1 point, but it's part of streamlining the portfolio toward higher-growth areas.

    **ALEX:** Classic port

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Intuitive Surgical Q3 2026 Earnings Analysis
    Oct 21 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're diving into Intuitive Surgical's Q3 2026 results — the robotic surgery giant behind the da Vinci system.

    **ALEX:** Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Good to have that out of the way. And Alex, this was a packed quarter — big numbers, a major legal settlement, pricing strategy shifts, even a new factory announcement in Malaysia.

    **ALEX:** Let's start with the headline numbers. Revenue grew 22% year-over-year to just over $3 billion, with 84% of that being recurring revenue — which, as always, is the magic of Intuitive's razor-and-blade business model.

    **JORDAN:** Right, and non-GAAP EPS grew 25% to $3 per share. Operating margin came in at 42%, or 41% if you strip out a one-time tariff refund. That's genuinely elite profitability for medtech.

    **ALEX:** But here's the asterisk — GAAP net income actually fell to $523 million, down from $704 million a year ago. Why the disconnect?

    **JORDAN:** That's the $450 million litigation settlement. Intuitive reached a no-fault agreement with customers in a class action lawsuit over third-party instrument remanufacturing and servicing. It's subject to court approval, expected sometime next year, but they took the charge now.

    **ALEX:** So basically, they're paying to put a messy legal issue behind them and get certainty on how they work with hospitals going forward.

    **JORDAN:** Exactly — CEO Dave Rosa framed it as removing a distraction so they can focus on advancing product safety and quality rather than litigating.

    **ALEX:** Let's talk procedures, because that's really the heartbeat of this business. Total procedures grew 15%, da Vinci procedures up 14%, and Ion — that's their lung biopsy platform — up a blazing 31%.

    **JORDAN:** The geographic split is interesting too. International da Vinci growth was 20%, while U.S. growth was 10% — and that 10% actually drew some pointed analyst questions on the call.

    **ALEX:** Yeah, an analyst from Wells Fargo flagged that 10% as the slowest U.S. growth since COVID. What was management's response?

    **JORDAN:** Dave Rosa basically said: don't panic, it's a tough comp — last year's Q3 grew 16%, their hardest comparison of the year. CFO Jamie Samath added more color, saying they're leaning into four growth levers: adding system capacity, especially for benign general surgery; pushing into ambulatory surgery centers, where ASC placements doubled over just two quarters; developing cardiac and breast procedures as emerging categories; and new indications in the R&D pipeline.

    **ALEX:** And speaking of placements — system placements overall were strong. 546 da Vinci systems placed globally, up 28%. The da Vinci 5, their newest platform, now makes up 65% of global placements combined with the single-port system.

    **JORDAN:** They've crossed 2,000 da Vinci 5 systems installed worldwide, used by over 18,000 surgeons. That's real traction for a platform that's still relatively new.

    **ALEX:** Now let's get into the pricing story, because this is a genuine strategic shift. Intuitive announced they're cutting instrument pricing on high-volume "benign" procedures — think hernia repairs, gallbladder removals, hysterectomies — stuff where laparoscopy has dominated because it's cheaper.

    **JORDAN:** They're extending the useful life of certain instruments and introducing volume-based pricing starting in 2027. The expected impact is a 3% to 5% reduction in da Vinci instrument-and-accessory revenue per procedure once fully rolled out.

    **ALEX:** That sounds l

    This episode includes AI-generated content.
    Show More Show Less
    9 mins
  • Abbott Laboratories Q3 2026 Earnings Analysis
    Oct 21 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

    **JORDAN:** And I'm Jordan. We've got a genuinely big one today — Abbott Laboratories dropped some major news alongside their Q3 numbers.

    **ALEX:** We'll get to that in a second, but first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** With that out of the way, Alex, let's start with the headline because it's not every day a 138-year-old company announces it's splitting itself in two.

    **ALEX:** Right — Abbott announced it's spinning off its entire nutrition business into a standalone, publicly traded company by the end of 2027. We're talking about Similac, PediaSure, Ensure, Glucerna, Pedialyte — the whole $8.5 billion nutrition empire, 16,000 employees, 14 manufacturing sites. CEO Robert Ford said this would actually be the largest pure-play healthy nutrition company in the world, and they expect it to qualify for S&P 500 inclusion on its own.

    **JORDAN:** And the CEO pick is interesting too — Daniel Salvadori, who's run their Established Pharma and Nutrition division, is taking the reins of the new company. Ford called his team "battle-tested," which, if you've followed Abbott's infant formula saga the last few years — recalls, litigation, supply shortages — that's not an exaggeration.

    **ALEX:** The strategic logic here is basically: nutrition used to be a healthcare-professional-driven category, now it's a consumer wellness category, and those two worlds need different playbooks, different investment cycles, different marketing muscle. Ford's view is both companies do better focused and independent rather than living under one roof.

    **JORDAN:** And for shareholders, it's structured as a tax-free spin — you'll own shares of both companies when it's done. Abbott's also planning to have the new nutrition company raise some debt, with proceeds flowing back to Abbott, and both companies will maintain investment-grade ratings.

    **ALEX:** What's the math on what's left behind? Because that's really the investor question here.

    **JORDAN:** Right, this is the key number. CFO Phil Boudreau said stripping nutrition out of the current portfolio, Abbott's remaining business — MedTech, Diagnostics, Established Pharma — would see sales growth accelerate by 50 to 100 basis points, gross margin expand by over 200 basis points, and operating margin up roughly 100 basis points. So the pitch is: a leaner, faster-growing, higher-margin Abbott emerges on the other side.

    **ALEX:** Now let's talk actual Q3 results, because they were solid. Sales grew 7%, EPS grew 9% — both numbers accelerating from the first half of the year. Adjusted EPS came in at $1.42, right in line with guidance and consensus.

    **JORDAN:** Breaking it down by segment — Diagnostics grew 6.5%, with Core Lab up 5.5% on strong demand across the U.S., Europe, Japan, and Latin America. But the real story there is Cancer Diagnostics, up 14%, largely thanks to the Exact Sciences integration — that's Cologuard. They also just launched their first blood-based colorectal cancer screening test in September, making Abbott the only company offering both stool-based and blood-based options.

    **ALEX:** Nutrition — even as it heads for the exit — actually had a good quarter. Sales up 5%, broad-based across all four categories. Pediatric nutrition was the standout at 9% growth, helped by those WIC contract wins that let Abbott reclaim market leadership.

    **JORDAN:** Medical Devices grew 8%, led by electrophysiology and rhythm management, both posting double-digit growth. The Volt PFA catheter is gaining serious traction after its

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • UnitedHealth Q3 2026 Earnings Analysis
    Oct 15 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    WELCOME TO BETA FINCH

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the jargon from corporate earnings calls and turn them into something you can actually digest. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into UnitedHealth Group — ticker UNH — and their third quarter 2026 results, reported this week.

    ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Good to have that out front. So Alex, this was actually a pretty encouraging quarter for UnitedHealth after a rough stretch.

    ALEX: It really was. Let's start with the headline numbers. Revenue came in at $113 billion for the quarter. Adjusted earnings per share was $4.69 — compare that to just $2.92 a year ago. That's a massive jump.

    JORDAN: And the metric everyone watches in this industry, the medical care ratio — basically what percentage of premium revenue goes out the door paying for medical claims — improved to 88.4%, down from 89.9% last year. Lower is better here, it means they're managing costs more effectively relative to what they're bringing in.

    ALEX: Right, and on the back of that they raised full-year guidance to at least $20.50 in adjusted EPS. CFO Wayne DeVeydt called that a "solid run rate to grow from," and interestingly, management said they think Wall Street's 2027 estimates might actually be too conservative.

    JORDAN: That's a confident thing to say out loud on an earnings call. They're essentially telling analysts, "you might be underestimating us."

    ALEX: Let's talk segments for a second. UnitedHealthcare, the insurance arm, served 48.3 million people. Optum, their services arm, posted $66.9 billion in revenue — though Optum Health specifically saw a 10% revenue decline, which sounds alarming at first.

    JORDAN: It does, but context matters. That's really a reflection of them pulling back from certain full-risk arrangements and refocusing on more disciplined, value-based care contracts rather than just chasing volume. Quality over quantity, essentially.

    ALEX: Now here's the thing that jumped out at me — commercial medical trend, meaning cost growth in their employer-sponsored insurance business, is running above 11%. That's way above historical norms.

    JORDAN: And they were pretty pointed about why. Two big drivers: high-cost specialty drugs, which is an industry-wide story at this point, and something more unique to UnitedHealth's commentary — arbitration awards tied to the No Surprises Act.

    ALEX: Explain that one, because it's a little wonky.

    JORDAN: Sure. The No Surprises Act was designed to protect patients from surprise out-of-network bills. But there's a dispute resolution process built into it, and UnitedHealth is saying certain provider groups are gaming that process — arbitration awards in some regions are approaching 6% of total medical spend. Management was blunt, calling it "abuse" of the system, and said it's translating to billions in excess costs.

    ALEX: So this isn't just "healthcare costs are high," it's "there's a specific regulatory mechanism being exploited."

    JORDAN: Exactly, and they're actively lobbying regulators on it. Worth watching into 2027.

    ALEX: Let's shift to the strategic story, because this is where it gets interesting. CEO Steve Hemsley leaned hard into AI throughout the call. They've rolled out AI-enabled chart summarization to over 40% of employed clinicians, cutting chart review time by a third. AI-assisted appeals processing cut cycle times by 26%.

    JORDAN: And the big one for anyone who's ever dealt with insurance red tape — they're on track to cut prior authorization volumes by 30%

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Medtronic Q1 2027 Earnings Analysis
    Sep 1 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    WELCOME TO BETA FINCH — MEDTRONIC Q1 FY2027

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Medtronic's fiscal 2027 first quarter — and it's a big one.

    JORDAN: Yeah, a lot to unpack here. Big beats, a couple of surprise M&A announcements, and a robotics story that's getting more interesting by the day.

    ALEX: Before we jump in, quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: With that out of the way, let's get into the numbers, because they were strong.

    ALEX: $9.8 billion in revenue, up 13.7% organically, adjusted EPS of $1.45 — both well ahead of what analysts were expecting. Now, a chunk of that growth came from an accounting quirk: fiscal 2027 is a 53-week year, and that extra week added about 670 basis points to growth this quarter.

    JORDAN: Right, but even stripping that out, CFO Thierry Piéton said it was their strongest quarterly performance in nearly eight years, excluding COVID comparisons. So this wasn't just a calendar trick — the underlying business is actually accelerating.

    ALEX: And it was broad-based. CEO Geoff Martha kept hammering that point — it's not one hot product carrying the quarter, it's basically every major business line pulling its weight.

    JORDAN: The headline story, though, is Cardiac Ablation Solutions — CAS. That business grew 88% worldwide, 139% in the U.S. They crossed $2 billion in trailing twelve-month revenue, ahead of schedule. Their Sphere-9 catheter picked up nine points of U.S. market share this quarter alone.

    ALEX: Nine points in one quarter is wild for medtech.

    JORDAN: It really is. And they're guiding CAS to grow at 2.5 times the broader electrophysiology market for the full year — even upgraded that to more than 3x for Q2. The U.S. installed base for their Affera system grew 35% sequentially, on top of 40% the quarter before.

    ALEX: Which tells you they're nowhere near saturated. Management said 75% of that installed base is still concentrated in high-volume hospital centers, so there's a long runway into smaller accounts.

    JORDAN: Beyond CAS, Cardiac Rhythm Management grew 15%, Cranial & Spinal Technologies grew 13%, and Surgical — their biggest unit at over $6 billion a year — grew 9%. Pelvic health jumped 15%, largely thanks to Altaviva, where procedures doubled sequentially.

    ALEX: Now let's talk strategy, because Medtronic made two acquisition-adjacent announcements the same morning as earnings. First, a $700 million strategic investment and distribution deal with Cornerstone Robotics for their Sentire surgical robot, outside the U.S.

    JORDAN: This one got some pointed questions on the call. One analyst basically asked, "Does this mean you've lost confidence in Hugo, your own robot?" And Martha pushed back hard — said it's the opposite. Hugo's on track to hit 50,000 procedures by year-end, growing at twice the market rate. Cornerstone is about extending reach into international markets where Hugo isn't the right fit, not replacing it.

    ALEX: Basically building a multi-platform robotics portfolio instead of betting everything on one system.

    JORDAN: Exactly — and Thierry noted the financial impact this year is minimal, mostly just some foregone interest on that investment, but they expect real revenue and margin lift starting in fiscal 2028.

    ALEX: The second deal was Pi-Cardia, in structural heart — first FDA-cleared technology for leaflet modification in TAVR procedures for patients at risk of coronary obstruction. That's part of a broader doubling-down in structural heart, alongside their earlier investment in Anteris.

    JORDAN: On guidance, they ra

    This episode includes AI-generated content.
    Show More Show Less
    7 mins